Aurinia Pharmaceuticals AUPH Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Aurinia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aurinia Pharmaceuticals's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aurinia Pharmaceuticals's additional paid-in capital?
- Aurinia Pharmaceuticals (AUPH) reported additional paid-in capital of $96.87M in Q1 2026.
- How has Aurinia Pharmaceuticals's additional paid-in capital changed year-over-year?
- Aurinia Pharmaceuticals's additional paid-in capital decreased by 4.1% year-over-year, from $100.98M to $96.87M.
- What is the long-term trend for Aurinia Pharmaceuticals's additional paid-in capital?
- Over 5 years (2020 to 2025), Aurinia Pharmaceuticals's additional paid-in capital has grown at a 23.1% compound annual growth rate (CAGR), from $39.38M to $111.26M.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.